Literature DB >> 7719412

Effect of leukotriene C4D4 antagonist on colonic damage induced by intracolonic administration of trinitrobenzene sulfonic acid in rats.

M Nishikawa1, Y Hikasa, K Hori, N Tanida, T Shimoyama.   

Abstract

We examined the effects of eicosanoid antagonists on colonic damage induced by trinitrobenzene sulfonic acid (TNB) in a rat inflammatory bowel model. TNB (30 mg) dissolved in 0.25 ml of 50% ethanol, was given intrarectally. The appropriate doses of ONO-1078 (a leukotriene C4D4 antagonist), ONO-4057 (a leukotriene B4 antagonist), and OKY-046 (a thromboxane A2 synthetase inhibitor) were given to obtain the same blood level, either 4 h before (pre-treatment model) or 24 h after (the post-treatment model) the administration of TNB (n = 8 in all groups). Drugs were given once daily for 6 days through a gastric feeding tube. Autopsy was performed on the 7th day. Colonic damage was assessed in terms of colonic damage scores, and myeloperoxidase (MPO) activity and eicosanoid concentrations in colonic tissues were measured. Compared with the group given TNB alone, the colonic damage score was reduced to 10% in the pre-treatment model with ONO-1078, but the score was not reduced in other groups, MPO activity was not changed in any group. The concentration of leukotriene C4 was reduced with ONO-1078 treatment, in both pre- and post-treatment models. These results demonstrated that a leukotriene C4D4 antagonist reduced colonic inflammation; however, its anti-inflammatory effect was limited in this colitis model.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7719412     DOI: 10.1007/bf01211372

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  26 in total

1.  Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4.

Authors:  E A Lobos; P Sharon; W F Stenson
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

2.  Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Gastroenterology       Date:  1986-10       Impact factor: 22.682

3.  Automated extraction and HPLC resolution of lipoxygenase and cyclooxygenase products utilizing high pressure column switching.

Authors:  W C Pickett; M B Douglas
Journal:  Prostaglandins       Date:  1985-01

4.  Abnormal metabolism of arachidonic acid in chronic inflammatory bowel disease: enhanced release of leucotriene B4 from activated neutrophils.

Authors:  O H Nielsen; I Ahnfelt-Rønne; J Elmgreen
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

5.  Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease.

Authors:  J L Wallace; W K MacNaughton; G P Morris; P L Beck
Journal:  Gastroenterology       Date:  1989-01       Impact factor: 22.682

6.  Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis.

Authors:  J Vilaseca; A Salas; F Guarner; R Rodriguez; J R Malagelada
Journal:  Gastroenterology       Date:  1990-02       Impact factor: 22.682

7.  The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat.

Authors:  N K Boughton-Smith; J L Wallace; G P Morris; B J Whittle
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

8.  Radioimmunoassay measurement of prostaglandins E, A, and F in human plasma.

Authors:  B M Jaffe; H R Behrman; C W Parker
Journal:  J Clin Invest       Date:  1973-02       Impact factor: 14.808

9.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

Authors:  J E Krawisz; P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

10.  Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.

Authors:  P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

View more
  6 in total

1.  Montelukast suppresses the development of irritable bowel syndrome phenotype possibly through modulating NF-κB signaling in an experimental model.

Authors:  Pariya Khodabakhsh; Nilgoon Khoie; Ahmad-Reza Dehpour; Alireza Abdollahi; Mahmoud Ghazi-Khansari; Hamed Shafaroodi
Journal:  Inflammopharmacology       Date:  2022-01-10       Impact factor: 4.473

Review 2.  Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer.

Authors:  Sayeh Savari; Katyayni Vinnakota; Yuan Zhang; Anita Sjölander
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 3.  Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer.

Authors:  Lorraine Burke; Clare T Butler; Adrian Murphy; Bruce Moran; William M Gallagher; Jacintha O'Sullivan; Breandán N Kennedy
Journal:  Front Cell Dev Biol       Date:  2016-09-21

4.  Cysteinyl leukotriene receptor 1 facilitates tumorigenesis in a mouse model of colitis-associated colon cancer.

Authors:  Janina Osman; Sayeh Savari; Naveen Kumar Chandrashekar; Kishan Bellamkonda; Desiree Douglas; Anita Sjölander
Journal:  Oncotarget       Date:  2017-05-23

5.  The effect of montelukast, a leukotriene receptor antagonist, on the acetic acid-induced model of colitis in rats: Involvement of NO-cGMP-KATP channels pathway.

Authors:  Behnam Ghorbanzadeh; Mohammad Amin Behmanesh; Roya Mahmoudinejad; Mehdi Zamaniyan; Shadi Ekhtiar; Yousef Paridar
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

6.  The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.

Authors:  Takuma Higurashi; Jun Arimoto; Keiichi Ashikari; Tomohiro Takatsu; Noboru Misawa; Tsutomu Yoshihara; Tetsuya Matsuura; Akiko Fuyuki; Hidenori Ohkubo; Atsushi Nakajima
Journal:  BMC Cancer       Date:  2020-08-17       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.